Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Q4 FY25 Earnings Presentation
16 slides from Nova Eye Medical's earnings presentation, Jul 31, 2025
Slide 1: Nova Eye Medical Limited (ASX:EYE) Investor Webinar
Nova Eye Medical Limited (ASX:EYE) Investor Webinar – quarterly report 30 June 2025 nova-eye.com | 1 31 July 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Highlights
Highlights • Another record full-year revenue of A$29.2 million for FY25, in line with guidance and 23% higher than pcp (in constant currency) • Glaucoma segment generated a positive EBITDA in H2 FY25, a substantial improvement on H1 and in line with guidance • Group cash outflow from operations has
Slide 4: Revenue by Sales Territory
Revenue by Sales Territory Growth US$'000’s FY24 H1FY25 Q3FY25 Q4FY25 H2FY25 FY25(1) on PCP USA 11,383 6,477 3,673 4,159 7,832 14,309 26% Germany 1,631 869 596 444 1,040 1,909 17% Rest of World 1,228 329 406 663 1,069 1,399 14% Sales (Excl China) 14,242 7,674 4,675 5,267 9,942 17,616 24% China 996 7
Slide 5: EBITDA for H2FY25 (unaudited)
EBITDA for H2FY25 (unaudited) US$000 (unaudited management H1FY25 H2FY25 accounts) ACT ACT FY25 ACT Revenue 8,384 10,393 18,777 COGS (2,878) (3,092) (5,970) Gross Margin 5,506 7,301 12,807 Gross Margin % 66% 71% 70% Less operating expenditure (7,382) (7,236) (14,618) EBITDA/(loss) glaucoma segment (
Slide 6: Cash outflow from operations continues to improve
Cash outflow from operations continues to improve Group cash outflow from operations Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 - -500 Cash Outlow in A$000s per qtr -1,000 -847 -1,161 -1,285 -1,500 -1,377 -1,515 -1,792 -2,000 -2,322 -2,500 -2,608 -3,000 • Earnings improvement ha
Slide 7: FY26 Guidance
FY26 Guidance • FY26 sales revenue (excluding China) expected to range between US$21 million and US$24 million (A$32 million to A$37 million at todays’ exchange rate) • The group is currently expected to achieve breakeven EBITDA in H1 FY26 • The resultant cash flow from operations is expected to imp
Slide 8: Interventional Glaucoma market is large and growing
Interventional Glaucoma market is large and growing • Traditional medication treatment paradigm is chronic medication use causes eye damage Patient adherence to glaucoma • The emerging interventional glaucoma (IG) approach medications is poor emphasizes early use of minimally invasive glaucoma surge
Slide 9: Clinically Significant Features of iTrack Advance vs Other MIGS
Clinically Significant Features of iTrack Advance vs Other MIGS FDA Light, indication Implant- 360o in Preserve Device Company Procedure Natural Outflow Pathway to treat free single s Tissue glaucoma pass Schlemm Collector TM ’s Canal Channels iTrackTM Nova Eye Advance Medical Canaloplasty ✓ ✓ ✓ ✓ ✓
Slide 10: Market Activation and Clinical Data
Market Activation and Clinical Data • Market activation and clinical activities in the quarter included participation in the 2025 World Glaucoma Congress (WGC) in Honolulu. Podium presentations of clinical data were extracted from the International Glaucoma Surgery Registry (IGSR). • The IGSR is the
Slide 11: USA reimbursement 2026 proposed rates are stable
USA reimbursement 2026 proposed rates are stable • Canaloplasty surgery has a well-established CPT1 code authorised by the USA CMS2. Eye surgeon selects Nova Eye delivers the The operating notes are submitted to Nova Eye product. product to the Facility and Medicare Administrative Contractor invoice
Slide 12: Needham & Co Rates EYE the fastest growing MIGS company in USA
Needham & Co Rates EYE the fastest growing MIGS company in USA • Needham & Co independent analysis based on interviews with 35 USA ophthalmologists. • Nova Eye share of USA market expected to grow from 2.4% to 3.4% in the 12 months ending June 2026 nova-eye.com | 12 • With a 2.4% market share USA re
Slide 13: China and iTrack Advance
China and iTrack Advance • Progressing approval by the regulatory authority in China of iTrack Advance. This process has been underway for approximately 15 months. • We are optimistic of securing approval later in the 2025 calendar year. In the meantime, sales in China of our original iTrack microca
Slide 14: Drug delivery with iTrack
Drug delivery with iTrack • The Company continues to assess opportunities leveraging its proprietary iTrack technology for targeted drug delivery within the eye. • The iTrack microcatheter is the world’s smallest and has been identified as being potentially capable of delivering therapeutic payloads
Slide 15: Critical Technologies Grant Award
Critical Technologies Grant Award • In July 2025 the Company, in conjunction with Adelaide University, was awarded a grant under the Australian Government’s “Critical Technologies Challenge Program” of $488,000. • The Company will leverage Adelaide University’s innovations in quantum technology and
Slide 16: Tom Spurling, Mark Flynn
Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8362 0193 +61 416 068 733 tspurling@nova-eye.com mflynn@nova-eye.com nova-eye.com | 16